|
|
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseEarly Phase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评估IM19 CAR-T细胞治疗复发或难治CD19阳性急性B淋巴细胞白血病的安全性和有效性的I/II期临床研究
[Translation] Phase I/II clinical study to evaluate the safety and efficacy of IM19 CAR-T cells in the treatment of relapsed or refractory CD19-positive acute B-lymphoblastic leukemia
I期阶段的主要目的为评估IM19 CAR-T细胞治疗3-25岁CD19阳性复发或难治的急性B淋巴细胞白血病患者的安全性、耐受性以及药代动力学特征,并确定推荐的Ⅱ期治疗剂量;II期阶段的主要目的为评估IM19 CAR-T细胞治疗3-25岁CD19 阳性复发或难治的急性B淋巴细胞白血病患者的疗效。
[Translation] The main purpose of the Phase I stage is to evaluate the safety, tolerability and pharmacokinetic characteristics of IM19 CAR-T cells in the treatment of patients with CD19-positive relapsed or refractory acute B-lymphoblastic leukemia aged 3-25 years, and to determine the recommended Phase II treatment dose; the main purpose of the Phase II stage is to evaluate the efficacy of IM19 CAR-T cells in the treatment of patients with CD19-positive relapsed or refractory acute B-lymphoblastic leukemia aged 3-25 years.
评估IM19 CAR-T细胞治疗复发或难治CD19阳性套细胞淋巴瘤患者的安全性和有效性的I/II期临床研究
[Translation] A phase I/II clinical study to evaluate the safety and efficacy of IM19 CAR-T cells in the treatment of patients with relapsed or refractory CD19-positive mantle cell lymphoma
主要目的:评估IM19 CAR-T细胞治疗复发或难治CD19 阳性套细胞淋巴瘤患者的安全性和疗效。
次要目的:评估IM19 CAR-T细胞治疗复发或难治的CD19阳性套细胞淋巴瘤患者的除90天ORR外的其它疗效指标、药代动力学特征及免疫原性。
[Translation] Primary objective: To evaluate the safety and efficacy of IM19 CAR-T cells in the treatment of patients with relapsed or refractory CD19-positive mantle cell lymphoma.
Secondary objective: To evaluate other efficacy indicators, pharmacokinetic characteristics and immunogenicity of IM19 CAR-T cells in the treatment of patients with relapsed or refractory CD19-positive mantle cell lymphoma, except for 90-day ORR.
评估 IM19CAR-T 细胞治疗复发或难治 CD19 阳性侵袭性非霍奇金淋巴瘤患者的安全性和有效性的 I/II 期临床研究
[Translation] A phase I/II clinical study to evaluate the safety and efficacy of IM19CAR-T cells in patients with relapsed or refractory CD19-positive aggressive non-Hodgkin's lymphoma
I期阶段的主要目的为评估IM19 CAR-T细胞治疗复发或难治CD19 阳性侵袭性非霍奇金淋巴瘤患者的安全性; II期阶段的主要目的为评估IM19 CAR-T细胞治疗复发或难治CD19阳性侵袭性非霍奇金淋巴瘤患者的疗效。
[Translation] The main purpose of the Phase I stage is to evaluate the safety of IM19 CAR-T cell therapy in patients with relapsed or refractory CD19-positive aggressive non-Hodgkin's lymphoma; the main purpose of the Phase II stage is to evaluate the efficacy of IM19 CAR-T cell therapy in patients with relapsed or refractory CD19-positive aggressive non-Hodgkin's lymphoma.
100 Clinical Results associated with Beijing Yimiao Medical Technology Co., Ltd.
0 Patents (Medical) associated with Beijing Yimiao Medical Technology Co., Ltd.
100 Deals associated with Beijing Yimiao Medical Technology Co., Ltd.
100 Translational Medicine associated with Beijing Yimiao Medical Technology Co., Ltd.